Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | TP53 | P04637 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | THPO | P40225 | 1/20 | 0.89 |
| ▸ | DRD4 | P21917 | 1/20 | 0.89 |
| ▸ | HTT | P42858 | 1/20 | 0.89 |
| ▸ | GMNN | O75496 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096472 | 1.00 | DRD3 (1.00) | DRD3SLC6A3DRD2MEN1MAPT | |
| Clobenztropine SCHEMBL1152891 | 0.94 | DRD3 (1.00) | DRD3SLC6A3DRD2MEN1MAPT | |
| Clobenztropine SCHEMBL137213 | 0.94 | DRD3 (1.00) | DRD3SLC6A3DRD2MEN1MAPT | |
| Clobenztropine SCHEMBL1152321 | 0.94 | DRD3 (1.00) | DRD3SLC6A3DRD2MEN1MAPT | |
| Clobenztropine SCHEMBL6678407 | 0.93 | MEN1 (1.00) | DRD3SLC6A3DRD2MEN1MAPT | |
| Clobenztropine SCHEMBL6675824 | 0.93 | MEN1 (1.00) | DRD3SLC6A3DRD2MEN1MAPT | |
| Clobenztropine SCHEMBL466951 | 0.93 | MEN1 (1.00) | DRD3SLC6A3DRD2MEN1MAPT | |
| Difluorobenztropine SCHEMBL23675084 | 0.84 | SLC6A3 (1.00) | DRD3SLC6A3DRD2CYP1A2CYP2D6 | |
| Difluorobenztropine SCHEMBL2615300 | 0.84 | SLC6A3 (1.00) | DRD3SLC6A3DRD2CYP1A2CYP2D6 | |
| Difluorobenztropine SCHEMBL6478352 | 0.84 | SLC6A3 (1.00) | DRD3SLC6A3DRD2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-20130202529-A1 | BENZTROPINE COMPOUNDS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-8383817-B2 | S-(+)-2 beta -hydroxymethyl-3 alpha -[bis(4-fluorophenyl)methoxy]tropane; treating mental disorders; reducing food intake; detecting the binding of the compound to the central nervous system tissue to monitor Parkinson's | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20080226559-A1 | Benztropine Compounds and Uses Thereof | GOVERNMENT OF THE USA,REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1919476-A2 | BENZTROPINE COMPOUNDS AND USES THEREOF AS DOPAMINE UPTAKE INHIBITORS | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007025055-A2 | BENZTROPINE COMPOUNDS AND USES THEREOF AS DOPAMINE UPTAKE INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | DRD3 4854/4885SLC6A3 4289/4885DRD2 4871/4885 |
| US-20130202529-A1 | BENZTROPINE COMPOUNDS AND USES THEREOF | OPRM1, MC2R, CNR1 | DRD3 16/4885SLC6A3 64/4885DRD2 32/4885 |
| US-20080226559-A1 | Benztropine Compounds and Uses Thereof | OPRM1, MC2R, OPRD1 | DRD3 20/4885SLC6A3 59/4885DRD2 29/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | DRD3 4854/4885SLC6A3 4289/4885DRD2 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.